Abstract
Imaging plays an integral role in the detection, diagnosis, staging, and management of lung and pleural tumors. This chapter presents a general overview of lung and pleural tumor imaging and describes the advantages and limitations of the different imaging modalities, including radiographs, computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI), in the workup of intrathoracic neoplasms. It illustrates the typical radiologic appearances of pulmonary tumors, including features that help distinguish benign entities from primary and secondary lung and pleural cancers, with emphasis on the complementary role of radiology with histologic analysis of tumor tissue. This chapter explains patterns of metastatic disease from primary intrathoracic tumors in addition to lung metastases from extrathoracic neoplasms. The staging systems for primary non-small cell lung cancers (7th edition), small-cell lung cancer, and malignant pleural mesothelioma, as well as the new classification of lung adenocarcinomas, are discussed. The guidelines of the American College of Chest Physicians for imaging utilization in malignancy staging are presented. This chapter intends to guide the reader to the best choice of imaging studies, to appropriately manage patients with intrathoracic tumors for correct selection of patients for potentially curative surgery.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Hulka BS. Cancer screening. Degrees of proof and practical application. Cancer. 1988;62(8 Suppl):1776–80.
Steele JD. The solitary pulmonary nodule. Report of a cooperative study of resected asymptomatic solitary pulmonary nodules in males. J Thorac Cardiovasc Surg. 1963;46:21–39.
Walske BR. The solitary pulmonary nodule: a review of 217 cases. Dis Chest. 1966;49:302–4.
Gurney JW. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. Radiology. 1993;186(2):405–13.
Yankelevitz DF, Henschke CI. Does 2-year stability imply that pulmonary nodules are benign? AJR Am J Roentgenol. 1997;168(2):325–8.
Berger WG, Erly WK, Krupinski EA, Standen JR, Stern RG. The solitary pulmonary nodule on chest radiography: can we really tell if the nodule is calcified? AJR Am J Roentgenol. 2001;176(1):201–4.
Black C, de Verteuil R, Walker S, Ayres J, Boland A, Bagust A, et al. Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. Thorax. 2007;62(2):131–8.
Heitzman ER, editor. The lung: radiologic-pathologic correlations. 2nd ed. St. Louis: CV Mosby; 1984.
Zwirewich CV, Vedal S, Miller RR, Muller NL. Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation. Radiology. 1991;179(2):469–76.
Siegelman SS, Khouri NF, Leo FP, Fishman EK, Braverman RM, Zerhouni EA. Solitary pulmonary nodules: CT assessment. Radiology. 1986;160(2):307–12.
Mahoney MC, Shipley RT, Corcoran HL, Dickson BA. CT demonstration of calcification in carcinoma of the lung. AJR Am J Roentgenol. 1990;154(2):255–8.
Siegelman SS, Zerhouni EA, Leo FP, Khouri NF, Stitik FP. CT of the solitary pulmonary nodule. AJR Am J Roentgenol. 1980;135(1):1–13.
Swensen SJ, Harms GF, Morin RL, Myers JL. CT evaluation of solitary pulmonary nodules: value of 185-H reference phantom. AJR Am J Roentgenol. 1991;156(5):925–9.
Siegelman SS, Khouri NF, Scott Jr WW, Leo FP, Hamper UM, Fishman EK, et al. Pulmonary hamartoma: CT findings. Radiology. 1986;160(2):313–7.
Kui M, Templeton PA, White CS, Cai ZL, Bai YX, Cai YQ. Evaluation of the air bronchogram sign on CT in solitary pulmonary lesions. J Comput Assist Tomogr. 1996;20(6):983–6.
Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D, Miettinen OS. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol. 2002;178(5):1053–7.
Swensen SJ, Morin RL, Schueler BA, Brown LR, Cortese DA, Pairolero PC, et al. Solitary pulmonary nodule: CT evaluation of enhancement with iodinated contrast material – a preliminary report. Radiology. 1992;182(2):343–7.
Swensen SJ, Viggiano RW, Midthun DE, Muller NL, Sherrick A, Yamashita K, et al. Lung nodule enhancement at CT: multicenter study. Radiology. 2000;214(1):73–80.
Bankier AA, O’Donnell CR, Boiselle PM. Quality initiatives. Respiratory instructions for CT examinations of the lungs: a hands-on guide. Radiographics. 2008;28(4):919–31.
Hasegawa M, Sone S, Takashima S, Li F, Yang ZG, Maruyama Y, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol. 2000;73(876):1252–9.
Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology. 2009;253(3):606–22.
Awaya H, Matsumoto T, Honjo K, Miura G, Emoto T, Matsunaga N. A preliminary study of discrimination among the components of small pulmonary nodules by MR imaging: correlation between MR images and histologic appearance. Radiat Med. 2000;18(1):29–38.
Cronin P, Dwamena BA, Kelly AM, Bernstein SJ, Carlos RC. Solitary pulmonary nodules and masses: a meta-analysis of the diagnostic utility of alternative imaging tests. Eur Radiol. 2008;8(9):1840–56.
Schaefer JF, Vollmar J, Schick F, Vonthein R, Seemann MD, Aebert H, et al. Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging–perfusion differences in malignant and benign lesions. Radiology. 2004;232(2):544–53.
Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR. PET and [18 F]-FDG in oncology: a clinical update. Nucl Med Biol. 1996;23(6):717–35.
Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285(7):914–24.
Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1992;184(2):441–4.
Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996;37(6):943–8.
Hubner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S, et al. Differentiating benign from malignant lung lesions using “quantitative” parameters of FDG PET images. Clin Nucl Med. 1996;21(12):941–9.
Patz Jr EF, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188(2):487–90.
Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The members of the PET-Lung Tumor Study Group. Ann Thorac Surg. 1994;58(3):698–703.
Jeong SY, Lee KS, Shin KM, Bae YA, Kim BT, Choe BK, et al. Efficacy of PET/CT in the characterization of solid or partly solid solitary pulmonary nodules. Lung Cancer. 2008;61:186–94. Epub 2008 Feb 15
Kernstine KH, Grannis Jr FW, Rotter AJ. Is there a role for PET in the evaluation of subcentimeter pulmonary nodules? Semin Thorac Cardiovasc Surg. 2005;17(2):110–4.
Marom EM, Sarvis S, Herndon 2nd JE, Patz Jr EF. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002;223(2):453–9.
Erasmus JJ, McAdams HP, Patz Jr EF, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998;170(5):1369–73.
Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39(6):1016–20.
Kim BT, Kim Y, Lee KS, Yoon SB, Cheon EM, Kwon OJ, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol. 1998;170(4):935–9.
Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16(3):1075–84.
Prauer HW, Weber WA, Romer W, Treumann T, Ziegler SI, Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg. 1998;85(11):1506–11.
Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med. 2005;46(9):1481–7.
Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest. 1993;104(4):997–1002.
Fletcher JW, Kymes SM, Gould M, Alazraki N, Coleman RE, Lowe VJ, et al. A comparison of the diagnostic accuracy of 18 F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med. 2008;49(2):179–85.
Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med. 1990;31(12):1927–32.
Marom EM, Erasmus JJ, Patz EF. Lung cancer and positron emission tomography with fluorodeoxyglucose. Lung Cancer. 2000;28(3):187–202.
Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM. Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. AJR Am J Roentgenol. 1995;164(6):1349–59.
Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32(4):623–48; discussion 649–50.
Bandi V, Lunn W, Ernst A, Eberhardt R, Hoffmann H, Herth FJ. Ultrasound vs. CT in detecting chest wall invasion by tumor: a prospective study. Chest. 2008;133(4):881–6.
Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8(6):541–52.
Hayata Y, Funatsu H, Kato H, Saito Y, Sawamura K, Furose K. Results of lung cancer screening programs in Japan. Recent Results Cancer Res. 1982;82:163–73.
Lilienfield A, Archer PG, Burnett CH, Chamberlain EW, Davis D, Davis RL. An evaluation of radiographic and cytologic screening for early detection of lung cancer: a cooperative pilot study of the American Cancer Society and the Veterans Administration. Cancer Res. 1966;26:2083–121.
Nash FA, Morgan JM, Tomkins JG. South London Lung Cancer Study. Br Med J. 1968;2(607):715–21.
Weiss W, Boucot KR. The Philadelphia Pulmonary Neoplasm Research Project. Early roentgenographic appearance of bronchogenic carcinoma. Arch Intern Med. 1974;134(2):306–11.
Brett GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax. 1968;23(4):414–20.
Wilde J. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Respir J. 1989;2(7):656–62.
Black WC, Welch HG. Screening for disease. AJR Am J Roentgenol. 1997;168(1):3–11.
Flehinger BJ, Melamed MR. Current status of screening for lung cancer. Chest Surg Clin N Am. 1994;4(1):1–15.
Fontana RS, Sanderson DR, Taylor WF, Woolner LB, Miller WE, Muhm JR, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis. 1984;130(4):561–5.
Frost JK, Ball Jr WC, Levin ML, Tockman MS, Baker RR, Carter D, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis. 1984;130(4):549–54.
Kubik A, Polak J. Lung cancer detection. Results of a randomized prospective study in Czechoslovakia. Cancer. 1986;57(12):2427–37.
Marcus PM, Bergstralh EJ, Fagerstrom RM, Williams DE, Fontana R, Taylor WF, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92(16):1308–16.
Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763–71.
Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA. 2007;297(9):953–61.
Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
Field JK, Baldwin D, Brain K, Devaraj A, Eisen T, Duffy SW, et al. CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report.Thorax. 2011;66(8):736–7. Epub 2011 Jul 1.
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker Jr S, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22(2):330–53.
Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348(25):2500–7.
Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343(4):254–61.
Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126(6):1943–51.
van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388–93.
Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16(6):2142–9.
Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer. 2004;44(2):175–81.
Rosado-de-Christenson ML, Templeton PA, Moran CA. Bronchogenic carcinoma: radiologic-pathologic correlation. Radiographics. 1994;14(2):429–46; quiz 447–8.
Sider L. Radiographic manifestations of primary bronchogenic carcinoma. Radiol Clin North Am. 1990;28(3):583–97.
Theros EG. 1976 Caldwell Lecture: varying manifestation of peripheral pulmonary neoplasms: a radiologic-pathologic correlative study. AJR Am J Roentgenol. 1977;128(6):893–914.
Woodring JH. Unusual radiographic manifestations of lung cancer. Radiol Clin North Am. 1990;28(3):599–618.
Kishi K, Homma S, Kurosaki A, Motoi N, Kohno T, Nakata K, et al. Small lung tumors with the size of 1 cm or less in diameter: clinical, radiological, and histopathological characteristics. Lung Cancer. 2004;44(1):43–51.
Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75(12):2844–52.
Takashima S, Li F, Maruyama Y, Hasegawa M, Takayama F, Kadoya M, et al. Discrimination of subtypes of small adenocarcinoma in the lung with thin-section CT. Lung Cancer. 2002;36(2):175–82.
Kondo T, Yamada K, Noda K, Nakayama H, Kameda Y. Radiologic-prognostic correlation in patients with small pulmonary adenocarcinomas. Lung Cancer. 2002;36(1):49–57.
Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H. Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact. Ann Thorac Surg. 2006;81(2):413–9.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.
Lee KS, Kim Y, Han J, Ko EJ, Park CK, Primack SL. Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings. Radiographics. 1997;17(6):1345–57.
Strollo DC, Rosado-de-Christenson ML, Franks TJ. Reclassification of cystic bronchioloalveolar carcinomas to adenocarcinomas based on the revised World Health Organization Classification of Lung and Pleural Tumours. J Thorac Imaging. 2003;18(2):59–66.
Weisbrod GL, Towers MJ, Chamberlain DW, Herman SJ, Matzinger FR. Thin-walled cystic lesions in bronchioalveolar carcinoma. Radiology. 1992;185(2):401–5.
Okubo K, Mark EJ, Flieder D, Wain JC, Wright CD, Moncure AC, et al. Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. J Thorac Cardiovasc Surg. 1999;118(4):702–9.
Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med. 2007;19(3):495–9.
Tsunezuka Y, Shimizu Y, Tanaka N, Takayanagi T, Kawano M. Positron emission tomography in relation to Noguchi’s classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size. World J Surg. 2007;31(2):314–7.
Byrd RB, Carr DT, Miller WE, Payne WS, Woolner LB. Radiographic abnormalities in carcinoma of the lung as related to histological cell type. Thorax. 1969;24(5):573–5.
Filderman AE, Shaw C, Matthay RA. Lung cancer. Part I: etiology, pathology, natural history, manifestations, and diagnostic techniques. Invest Radiol. 1986;21(1):80–90.
Shin MS, Jackson LK, Shelton Jr RW, Greene RE. Giant cell carcinoma of the lung. Clinical and roentgenographic manifestations. Chest. 1986;89(3):366–9.
Garcia-Yuste M, Matilla JM, Cueto A, Paniagua JM, Ramos G, Canizares MA, et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of neuroendocrine tumours of the lung. Eur J Cardiothorac Surg. 2007;31(2):192–7.
Zwiebel BR, Austin JH, Grimes MM. Bronchial carcinoid tumors: assessment with CT of location and intratumoral calcification in 31 patients. Radiology. 1991;179(2):483–6.
McCaughan BC, Martini N, Bains MS. Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg. 1985;89(1):8–17.
Muller NL, Miller RR. Neuroendocrine carcinomas of the lung. Semin Roentgenol. 1990;25(1):96–104.
Valli M, Fabris GA, Dewar A, Hornall D, Sheppard MN. Atypical carcinoid tumour of the lung: a study of 33 cases with prognostic features. Histopathology. 1994;24(4):363–9.
Chong S, Lee KS, Kim BT, Choi JY, Yi CA, Chung MJ, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188(5):1223–31.
Urschel JD. Surgical treatment of peripheral small cell lung cancer. Chest Surg Clin N Am. 1997;7(1):95–103.
Govindan R, Ihde DC. Practical issues in the management of the patient with small cell lung cancer. Chest Surg Clin N Am. 1997;7(1):167–81.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.
Ahuja V, Coleman RE, Herndon J, Patz Jr EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83(5):918–24.
Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3(1):6–12.
Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol. 2008;3(2):130–4.
Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33(5):819–23.
Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178(3):705–13.
Ratto GB, Piacenza G, Frola C, Musante F, Serrano I, Giua R, et al. Chest wall involvement by lung cancer: computed tomographic detection and results of operation. Ann Thorac Surg. 1991;51(2):182–8.
Padovani B, Mouroux J, Seksik L, Chanalet S, Sedat J, Rotomondo C, et al. Chest wall invasion by bronchogenic carcinoma: evaluation with MR imaging. Radiology. 1993;187(1):33–8.
Glazer HS, Kaiser LR, Anderson DJ, Molina PL, Emami B, Roper CL, et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1989;173(1):37–42.
Herman SJ, Winton TL, Weisbrod GL, Towers MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology. 1994;190(3):841–6.
McLoud TC. CT of bronchogenic carcinoma: indeterminate mediastinal invasion. Radiology. 1989;173(1):15–6.
Martini N, Heelan R, Westcott J, Bains MS, McCormack P, Caravelli J, et al. Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma. J Thorac Cardiovasc Surg. 1985;90(5):639–48.
Komaki R, Roth JA, Walsh GL, Putnam JB, Vaporciyan A, Lee JS, et al. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas MD. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2000;48(2):347–54.
Bruzzi JF, Komaki R, Walsh GL, Truong MT, Gladish GW, Munden RF, et al. Imaging of non-small cell lung cancer of the superior sulcus: part 1: anatomy, clinical manifestations, and management. Radiographics. 2008;28(2):551–60; quiz 620.
Dartevelle P, Macchiarini P. Surgical management of superior sulcus tumors. Oncologist. 1999;4(5):398–407.
Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol. 1985;144(2):261–5.
Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s–meta-analytic comparison of PET and CT. Radiology. 1999;213(2):530–6.
Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139(11):879–92.
Klein JS, Webb WR. The radiologic staging of lung cancer. J Thorac Imaging. 1991;7(1):29–47.
Musset D, Grenier P, Carette MF, Frija G, Hauuy MP, Desbleds MT, et al. Primary lung cancer staging: prospective comparative study of MR imaging with CT. Radiology. 1986;160(3):607–11.
Staples CA, Muller NL, Miller RR, Evans KG, Nelems B. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology. 1988;167(2):367–72.
Webb WR. MR imaging in the evaluation and staging of lung cancer. Semin Ultrasound CT MR. 1988;9(1):53–66.
Gdeedo A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J. 1997;10(7):1547–51.
McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JA, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992;182(2):319–23.
Kim HY, Yi CA, Lee KS, Chung MJ, Kim YK, Choi BK, et al. Nodal metastasis in non-small cell lung cancer: accuracy of 3.0-T MR imaging. Radiology. 2008;246(2):596–604.
Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248(2):632–42.
Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229(2):526–33.
Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123(1 Suppl):137S–46.
Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;79(1):375–82.
Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. Lung Cancer. 2008;60(1):62–8.
de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg. 2006;29(1):26–9.
Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000;27(11):1598–609.
Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg. 1998;66(6):1876–83; discussion 1883–5.
Spiro SG, Porter JC. Lung cancer – where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 2002;166(9):1166–96.
The American Thoracic Society and The European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med. 1997;156(1):320–32.
Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol. 2000;175(1):245–9.
Schaffler GJ, Wolf G, Schoellnast H, Groell R, Maier A, Smolle-Juttner FM, et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18 F FDG PET. Radiology. 2004;231(3):858–65.
Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest. 2004;125(6):2356–60.
Grant D, Edwards D, Goldstraw P. Computed tomography of the brain, chest, and abdomen in the preoperative assessment of non-small cell lung cancer. Thorax. 1988;43(11):883–6.
Silvestri GA, Lenz JE, Harper SN, Morse RA, Colice GL. The relationship of clinical findings to CT scan evidence of adrenal gland metastases in the staging of bronchogenic carcinoma. Chest. 1992;102(6):1748–51.
Tanaka K, Kubota K, Kodama T, Nagai K, Nishiwaki Y. Extrathoracic staging is not necessary for non-small-cell lung cancer with clinical stage T1-2 N0. Ann Thorac Surg. 1999;68(3):1039–42.
Figlin RA, Piantadosi S, Feld R. Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. N Engl J Med. 1988;318(20):1300–5.
Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol. 2001;19(5):1344–9.
Pagani JJ. Non-small cell lung carcinoma adrenal metastases. Computed tomography and percutaneous needle biopsy in their diagnosis. Cancer. 1984;53(5):1058–60.
Allard P, Yankaskas BC, Fletcher RH, Parker LA, Halvorsen Jr RA. Sensitivity and specificity of computed tomography for the detection of adrenal metastatic lesions among 91 autopsied lung cancer patients. Cancer. 1990;66(3):457–62.
Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):178S–201.
Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998;25(9):1244–7.
Erasmus JJ, Patz Jr EF, McAdams HP, Murray JG, Herndon J, Coleman RE, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18 F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168(5):1357–60.
Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212(3):803–9.
Englemen RM, McNamara WL. Bronchogenic carcinoma: a statistical review of two hundred twenty four autopsies. J Thorac Surg. 1954;27:227–37.
Mathews MJ, Kanhouwa S, Pickren J, Robinette D. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Treat Red. 1973;4:63–7.
Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz Jr EF, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007;2(8):686–93.
Bury T, Dowlati A, Paulus P, Corhay JL, Hustinx R, Ghaye B, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J. 1997;10(11):2529–34.
Bury T, Dowlati A, Paulus P, Hustinx R, Radermecker M, Rigo P. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med. 1996;23(2):204–6.
Erasmus JJ, Munden RF. The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol. 2007;17(1):29–37.
Ettinghausen SE, Burt ME. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. J Clin Oncol. 1991;9(8):1462–6.
Nielsen Jr ME, Heaston DK, Dunnick NR, Korobkin M. Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma. AJR Am J Roentgenol. 1982;139(2):317–20.
Oliver Jr TW, Bernardino ME, Miller JI, Mansour K, Greene D, Davis WA. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology. 1984;153(1):217–8.
Pagani JJ. Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy. AJR Am J Roentgenol. 1983;140(5):949–51.
Pagani JJ, Bernardino ME. Incidence and significance of serendipitous CT findings in the oncologic patient. J Comput Assist Tomogr. 1982;6(2):268–75.
Sparup J, Friis M, Brenoe J, Vejlsted H, Villumsen B, Olesen KP, et al. Computed tomography and the TNM classification of lung cancer. Scand J Thorac Cardiovasc Surg. 1990;24(3):207–11.
Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201–4.
Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology. 2000;217(3):798–802.
Schwartz LH, Ginsberg MS, Burt ME, Brown KT, Getrajdman GI, Panicek DM. MRI as an alternative to CT-guided biopsy of adrenal masses in patients with lung cancer. Ann Thorac Surg. 1998;65(1):193–7.
Outwater EK, Siegelman ES, Huang AB, Birnbaum BA. Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology. 1996;200(3):749–52.
Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;194(1):131–4.
Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics. 2001;21(4):995–1012.
Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 1F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42(12):1795–9.
Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol. 2007;14(4):468–75.
Hustinx R, Paulus P, Jacquet N, Jerusalem G, Bury T, Rigo P. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol. 1998;9(4):397–401.
Patz Jr EF, Erasmus JJ, McAdams HP, Connolly JE, Marom EM, Goodman PC, et al. Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology. 1999;212(1):56–60.
Butler AR, Leo JS, Lin JP, Boyd AD, Kricheff II. The value of routine cranial computed tomography in neurologically intact patients with primary carcinoma of the lung. Radiology. 1979;131(2):399–401.
Cole Jr FH, Thomas JE, Wilcox AB, Halford 3rd HH. Cerebral imaging in the asymptomatic preoperative bronchogenic carcinoma patient: is it worthwhile? Ann Thorac Surg. 1994;57(4):838–40.
Jacobs L, Kinkel WR, Vincent RG. ‘Silent’ brain metastasis from lung carcinoma determined by computerized tomography. Arch Neurol. 1977;34(11):690–3.
Jennings EC, Aungst CW, Yatco R. Asymptomatic patients with primary carcinomia; computerized axial tomography study. N Y State J Med. 1980;80(7 Pt 1):1096–8.
Kormas P, Bradshaw JR, Jeyasingham K. Preoperative computed tomography of the brain in non-small cell bronchogenic carcinoma. Thorax. 1992;47(2):106–8.
Osada H, Kojima K, Tsukada H, Nakajima Y, Imamura K, Matsumoto J. Cost-effectiveness associated with the diagnosis and staging of non-small-cell lung cancer. Jpn J Thorac Cardiovasc Surg. 2001;49(1):1–10.
Osada H, Nakajima Y, Taira Y, Yokote K, Noguchi T. The role of mediastinal and multi-organ CT scans in staging presumable surgical candidates with non-small-cell lung cancer. Jpn J Surg. 1987;17(5):362–8.
Yokoi K, Kamiya N, Matsuguma H, Machida S, Hirose T, Mori K, et al. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest. 1999;115(3):714–9.
Bilgin S, Yilmaz A, Ozdemir F, Akkaya E, Karakurt Z, Poluman A. Extrathoracic staging of non-small cell bronchogenic carcinoma: relationship of the clinical evaluation to organ scans. Respirology. 2002;7(1):57–61.
Crane JM, Nelson MJ, Ihde DC, Makuch RW, Glatstein E, Zabell A, et al. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. J Clin Oncol. 1984;2(9):1017–24.
Habets JM, van Oosterhout AG, ten Velde GP, Wilmink JT, Twijnstra A. Diagnostic value of CT in the detection of brain metastasis in small cell lung cancer patients. J Belge Radiol. 1992;75(3):179–81.
Hooper RG, Tenholder MF, Underwood GH, Beechler CR, Spratling L. Computed tomographic scanning of the brain in initial staging of bronchogenic carcinoma. Chest. 1984;85(6):774–6.
Johnson DH, Windham WW, Allen JH, Greco FA. Limited value of CT brain scans in the staging of small cell lung cancer. AJR Am J Roentgenol. 1983;140(1):37–40.
Levitan N, Hong WK, Byrne RE, Gale ME, Bromer RH, Levine HL, et al. Role of computerized cranial tomography in the staging of small cell carcinoma of the lung. Cancer Treat Rep. 1984;68(11):1375–7.
Mintz BJ, Tuhrim S, Alexander S, Yang WC, Shanzer S. Intracranial metastases in the initial staging of bronchogenic carcinoma. Chest. 1984;86(6):850–3.
Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest. 1990;97(5):1052–8.
Tarver RD, Richmond BD, Klatte EC. Cerebral metastases from lung carcinoma: neurological and CT correlation. Work in progress. Radiology. 1984;153(3):689–92.
Earnest FT, Ryu JH, Miller GM, Luetmer PH, Forstrom LA, Burnett OL, et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection – pilot study. Radiology. 1999;211(1):137–45.
Schirrmeister H, Arslandemir C, Glatting G, Mayer-Steinacker R, Bommer M, Dreinhofer K, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31(7):964–8.
Hsia TC, Shen YY, Yen RF, Kao CH, Changlai SP. Comparing whole body 18 F-2-deoxyglucose positron emission tomography and technetium-99 m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma. 2002;49(4):267–71.
Darling GE. Staging of the patient with small cell lung cancer. Chest Surg Clin N Am. 1997;7(1):81–94.
Jelinek JS, Redmond 3rd J, Perry JJ, Burrell LM, Benedikt RA, Geyer CA, et al. Small cell lung cancer: staging with MR imaging. Radiology. 1990;177(3):837–42.
Samson DJ, Seidenfeld J, Simon GR, Turrisi 3rd AT, Bonnell C, Ziegler KM, et al. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):314S–23.
Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol. 2004;27(2):164–71.
Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22(16):3248–54.
Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18 F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31(12):1614–20.
Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003;44(12):1911–7.
Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med. 2001;28(4):483–8.
Shen YY, Shiau YC, Wang JJ, Ho ST, Kao CH. Whole-body 18 F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res. 2002;22(2B):1257–64.
Niho S, Fujii H, Murakami K, Nagase S, Yoh K, Goto K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer. 2007;57(3):328–33.
Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer. 2008;9(1):30–4.
Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol. 2007;30(1):45–50.
Abrams J, Doyle LA, Aisner J. Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol. 1988;15(3):261–77.
Stahel RA, Mabry M, Skarin AT, Speak J, Bernal SD. Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. J Clin Oncol. 1985;3(4):455–61.
Hochstenbag MM, Twijnstra A, Wilmink JT, Wouters EF, ten Velde GP. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol. 2000;48(3):243–8.
Ishida T, Tateishi M, Kaneko S, Yano T, Mitsudomi T, Sugimachi K, et al. Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg. 1990;100(6):844–52.
Kim KI, Flint JD, Muller NL. Pulmonary carcinosarcoma: radiologic and pathologic findings in three patients. AJR Am J Roentgenol. 1997;169(3):691–4.
Nappi O, Glasner SD, Swanson PE, Wick MR. Biphasic and monophasic sarcomatoid carcinomas of the lung. A reappraisal of “carcinosarcomas” and “spindle-cell carcinomas”. Am J Clin Pathol. 1994;102(3):331–40.
Wick MR, Ritter JH, Humphrey PA. Sarcomatoid carcinomas of the lung: a clinicopathologic review. Am J Clin Pathol. 1997;108(1):40–53.
Kim K, Flint JDA, Muller NL. Pulmonary carcinosarcoma: radiologic and pathologic findings in three patients. Am J Roentgenol. 1997;169:691–4.
Boldrini R, Devito R, Diomedi-Camassei F, Francalanci P, Inserra A, Boglino C, et al. Pulmonary blastomas of childhood: histologic, immunohistochemical, ultrastructural aspects and therapeutic considerations. Ultrastruct Pathol. 2005;29(6):493–501.
Francis D, Jacobsen M. Pulmonary blastoma. Curr Top Pathol. 1983;73:265–94.
Liman ST, Altinok T, Topcu S, Tastepe AI, Uzar A, Demircan S, et al. Survival of biphasic pulmonary blastoma. Respir Med. 2006;100(7):1174–9.
Weisbrod GL, Chamberlain DW, Tao LC. Pulmonary blastoma, report of three cases and a review of the literature. Can Assoc Radiol J. 1988;39(2):130–6.
LeMense GP, Reed CE, Silvestri GA. Pulmonary blastoma: a rare lung malignancy. Lung Cancer. 1996;15(2):233–7.
Allen MS. Malignant tracheal tumors. Mayo Clin Proc. 1993;68(7):680–4.
Conlan AA, Payne WS, Woolner LB, Sanderson DR. Adenoid cystic carcinoma (cylindroma) and mucoepidermoid carcinoma of the bronchus. Factors affecting survival. J Thorac Cardiovasc Surg. 1978;76(3):369–77.
Dalton ML, Gatling RR. Peripheral adenoid cystic carcinoma of the lung. South Med J. 1990;83(5):577–9.
Gallagher CG, Stark R, Teskey J, Kryger M. Atypical manifestations of pulmonary adenoid cystic carcinoma. Br J Dis Chest. 1986;80(4):396–9.
McCarthy MJ, Rosado-de-Christenson ML. Tumors of the trachea. J Thorac Imaging. 1995;10(3):180–98.
Spizarny DL, Shepard JA, McLoud TC, Grillo HC, Dedrick CG. CT of adenoid cystic carcinoma of the trachea. AJR Am J Roentgenol. 1986;146(6):1129–32.
Trentini GP, Palmieri B. Mucoepidermoid tumor of the trachea. Chest. 1972;62(3):336–8.
Turnbull AD, Huvos AG, Goodner JT, Foote Jr FW. Mucoepidermoid tumors of bronchial glands. Cancer. 1971;28(3):539–44.
Yousem SA, Hochholzer L. Mucoepidermoid tumors of the lung. Cancer. 1987;60(6):1346–52.
Klacsmann PG, Olson JL, Eggleston JC. Mucoepidermoid carcinoma of the bronchus: an electron microscopic study of the low grade and the high grade variants. Cancer. 1979;43(5):1720–33.
Spencer H. Bronchial mucous gland tumours. Virchows Arch. 1979;383(1):101–15.
Katz DS, Lane MJ, Leung AN, Marcus FS, Sakata MK. Primary malignant pulmonary hemangiopericytoma. Clin Imaging. 1998;22(3):192–5.
Moran CA, Suster S, Abbondanzo SL, Koss MN. Primary leiomyosarcomas of the lung: a clinicopathologic and immunohistochemical study of 18 cases. Mod Pathol. 1997;10(2):121–8.
Suster S. Primary sarcomas of the lung. Semin Diagn Pathol. 1995;12(2):140–57.
Zeren H, Moran CA, Suster S, Fishback NF, Koss MN. Primary pulmonary sarcomas with features of monophasic synovial sarcoma: a clinicopathological, immunohistochemical, and ultrastructural study of 25 cases. Hum Pathol. 1995;26(5):474–80.
Attanoos RL, Appleton MA, Gibbs AR. Primary sarcomas of the lung: a clinicopathological and immunohistochemical study of 14 cases. Histopathology. 1996;29(1):29–36.
Janssen JP, Mulder JJ, Wagenaar SS, Elbers HR, van den Bosch JM. Primary sarcoma of the lung: a clinical study with long-term follow-up. Ann Thorac Surg. 1994;58(4):1151–5.
Yousem SA, Hochholzer L. Primary pulmonary hemangiopericytoma. Cancer. 1987;59(3):549–55.
Halle M, Blum U, Dinkel E, Brugger W. CT and MR features of primary pulmonary hemangiopericytomas. J Comput Assist Tomogr. 1993;17(1):51–5.
Lorigan JG, David CL, Evans HL, Wallace S. The clinical and radiologic manifestations of hemangiopericytoma. AJR Am J Roentgenol. 1989;153(2):345–9.
Yilmaz E, Akkoclu A, Kargi A, Sevinc C, Komus N, Catalyurek H, et al. Radiography, Doppler sonography, and MR angiography of malignant pulmonary hemangiopericytoma. AJR Am J Roentgenol. 2003;181(4):1079–81.
Bagan P, Hassan M, Le Pimpec Barthes F, Peyrard S, Souilamas R, Danel C, et al. Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature. Ann Thorac Surg. 2006;82(6):2010–3.
Weiss SW, Ishak KG, Dail DH, Sweet DE, Enzinger FM. Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol. 1986;3(4):259–87.
Dail DH, Liebow AA, Gmelich JT, Friedman PJ, Miyai K, Myer W, et al. Intravascular, bronchiolar, and alveolar tumor of the lung (IVBAT). An analysis of twenty cases of a peculiar sclerosing endothelial tumor. Cancer. 1983;51(3):452–64.
Ross GJ, Violi L, Friedman AC, Edmonds PR, Unger E. Intravascular bronchioloalveolar tumor: CT and pathologic correlation. J Comput Assist Tomogr. 1989;13(2):240–3.
Sakamoto N, Adachi S, Monzawa S, Hamanaka A, Takada Y, Hunada Y, et al. High resolution CT findings of pulmonary epithelioid hemangioendothelioma: unusual manifestations in 2 cases. J Thorac Imaging. 2005;20(3):236–8.
Bragg DG, Chor PJ, Murray KA, Kjeldsberg CR. Lymphoproliferative disorders of the lung: histopathology, clinical manifestations, and imaging features. AJR Am J Roentgenol. 1994;163(2):273–81.
Cordier JF, Chailleux E, Lauque D, Reynaud-Gaubert M, Dietemann-Molard A, Dalphin JC, et al. Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest. 1993;103(1):201–8.
Fiche M, Caprons F, Berger F, Galateau F, Cordier JF, Loire R, et al. Primary pulmonary non-Hodgkin’s lymphomas. Histopathology. 1995;26(6):529–37.
Nicholson A, Harris N. Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type. In: Travis WDBE, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumors: tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004. p. 88–90.
Ramani S, Karnad AB. Primary pulmonary non-Hodgkin’s lymphoma. South Med J. 1995;88(2):243–5.
Saltzstein SL. Pulmonary malignant lymphomas and pseudolymphomas: classification, therapy, and prognosis. Cancer. 1963;16:928–55.
Toh HC, Ang PT. Primary pulmonary lymphoma–clinical review from a single institution in Singapore. Leuk Lymphoma. 1997;27(1–2):153–63.
King LJ, Padley SP, Wotherspoon AC, Nicholson AG. Pulmonary MALT lymphoma: imaging findings in 24 cases. Eur Radiol. 2000;10(12):1932–8.
Koss MN. Pulmonary lymphoid disorders. Semin Diagn Pathol. 1995;12(2):158–71.
Lee KS, Kim Y, Primack SL. Imaging of pulmonary lymphomas. AJR Am J Roentgenol. 1997;168(2):339–45.
Li G, Hansmann ML, Zwingers T, Lennert K. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology. 1990;16(6):519–31.
O’Donnell PG, Jackson SA, Tung KT, Hassan B, Wilkins B, Mead GM. Radiological appearances of lymphomas arising from mucosa-associated lymphoid tissue (MALT) in the lung. Clin Radiol. 1998;53(4):258–63.
Kennedy JL, Nathwani BN, Burke JS, Hill LR, Rappaport H. Pulmonary lymphomas and other pulmonary lymphoid lesions. A clinicopathologic and immunologic study of 64 patients. Cancer. 1985;56(3):539–52.
Crow J, Slavin G, Kreel L. Pulmonary metastasis: a pathologic and radiologic study. Cancer. 1981;47(11):2595–602.
Hirakata K, Nakata H, Haratake J. Appearance of pulmonary metastases on high-resolution CT scans: comparison with histopathologic findings from autopsy specimens. AJR Am J Roentgenol. 1993;161(1):37–43.
Primack SL, Lee KS, Logan PM, Miller RR, Muller NL. Bronchogenic carcinoma: utility of CT in the evaluation of patients with suspected lesions. Radiology. 1994;193(3):795–800.
Clagett OT, Woolner LB. Surgical treatment of solitary metastatic pulmonary lesion. Med Clin North Am. 1964;48:939–43.
Toomes H, Delphendahl A, Manke HG, Vogt-Moykopf I. The coin lesion of the lung. A review of 955 resected coin lesions. Cancer. 1983;51(3):534–7.
Chaudhuri MR. Cavitary pulmonary metastases. Thorax. 1970;25(3):375–81.
Dodd GD, Boyle JJ. Excavating pulmonary metastases. Am J Roentgenol Radium Ther Nucl Med. 1961;85:277–93.
Seo JB, Im JG, Goo JM, Chung MJ, Kim MY. Atypical pulmonary metastases: spectrum of radiologic findings. Radiographics. 2001;21(2):403–17.
Libshitz HI, North LB. Pulmonary metastases. Radiol Clin North Am. 1982;20(3):437–51.
Patel AM, Ryu JH. Angiosarcoma in the lung. Chest. 1993;103(5):1531–5.
Franchi M, La Fianza A, Babilonti L, Bolis PF, Dore R, Legnani L, et al. Serous carcinoma of the ovary: value of computed tomography in detection of calcified pleural and pulmonary metastatic implants. Gynecol Oncol. 1990;39(1):85–8.
Hall FM, Frank HA, Cohen RB, Ezpeleta ML. Ossified pulmonary metastases from giant cell tumor of bone. AJR Am J Roentgenol. 1976;127(6):1046–7.
Jimenez JM, Casey SO, Citron M, Khan A. Calcified pulmonary metastases from medullary carcinoma of the thyroid. Comput Med Imaging Graph. 1995;19(4):325–8.
Gaeta M, Blandino A, Scribano E, Minutoli F, Volta S, Pandolfo I. Computed tomography halo sign in pulmonary nodules: frequency and diagnostic value. J Thorac Imaging. 1999;14(2):109–13.
Kim Y, Lee KS, Jung KJ, Han J, Kim JS, Suh JS. Halo sign on high resolution CT: findings in spectrum of pulmonary diseases with pathologic correlation. J Comput Assist Tomogr. 1999;23(4):622–6.
Primack SL, Hartman TE, Lee KS, Muller NL. Pulmonary nodules and the CT halo sign. Radiology. 1994;190(2):513–5.
Filderman AE, Coppage L, Shaw C, Matthay RA. Pulmonary and pleural manifestations of extrathoracic malignancies. Clin Chest Med. 1989;10(4):747–807.
Levin B. Subpleural interlobular lymphectasia reflecting metastatic carcinoma. Radiology. 1959;72(5):682–8.
Munk PL, Muller NL, Miller RR, Ostrow DN. Pulmonary lymphangitic carcinomatosis: CT and pathologic findings. Radiology. 1988;166(3):705–9.
Janower ML, Blennerhassett JB. Lymphangitic spread of metastatic cancer to the lung. A radiologic-pathologic classification. Radiology. 1971;101(2):267–73.
Sadoff L, Grossman J, Weiner H. Lymphangitic pulmonary metastases secondary to breast cancer with normal chest x-rays and abnormal perfusion lung scans. Oncology. 1975;31(3–4):164–71.
Grenier P, Chevret S, Beigelman C, Brauner MW, Chastang C, Valeyre D. Chronic diffuse infiltrative lung disease: determination of the diagnostic value of clinical data, chest radiography, and CT and Bayesian analysis. Radiology. 1994;191(2):383–90.
Stein MG, Mayo J, Muller N, Aberle DR, Webb WR, Gamsu G. Pulmonary lymphangitic spread of carcinoma: appearance on CT scans. Radiology. 1987;162(2):371–5.
Ren H, Hruban RH, Kuhlman JE, Fishman EK, Wheeler PS, Zerhouni EA, et al. Computed tomography of inflation-fixed lungs: the beaded septum sign of pulmonary metastases. J Comput Assist Tomogr. 1989;13(3):411–6.
Kane RD, Hawkins HK, Miller JA, Noce PS. Microscopic pulmonary tumor emboli associated with dyspnea. Cancer. 1975;36(4):1473–82.
Winterbauer RH, Elfenbein IB, Ball Jr WC. Incidence and clinical significance of tumor embolization to the lungs. Am J Med. 1968;45(2):271–90.
Chan CK, Hutcheon MA, Hyland RH, Smith GJ, Patterson BJ, Matthay RA. Pulmonary tumor embolism: a critical review of clinical, imaging, and hemodynamic features. J Thorac Imaging. 1987;2(4):4–14.
Kang CH, Choi JA, Kim HR, Oh YH, Kim HK, Kang EY. Lung metastases manifesting as pulmonary infarction by mucin and tumor embolization: radiographic, high-resolution CT, and pathologic findings. J Comput Assist Tomogr. 1999;23(4):644–6.
Kim AE, Haramati LB, Janus D, Borczuk A. Pulmonary tumor embolism presenting as infarcts on computed tomography. J Thorac Imaging. 1999;14(2):135–7.
Shepard JA, Moore EH, Templeton PA, McLoud TC. Pulmonary intravascular tumor emboli: dilated and beaded peripheral pulmonary arteries at CT. Radiology. 1993;187(3):797–801.
Franquet T, Gimenez A, Prats R, Rodriguez-Arias JM, Rodriguez C. Thrombotic microangiopathy of pulmonary tumors: a vascular cause of tree-in-bud pattern on CT. AJR Am J Roentgenol. 2002;179(4):897–9.
Tack D, Nollevaux MC, Gevenois PA. Tree-in-bud pattern in neoplastic pulmonary emboli. AJR Am J Roentgenol. 2001;176(6):1421–2.
Albertini RE, Ekberg NL. Endobronchial metastasis in breast cancer. Thorax. 1980;35(6):435–40.
Amer E, Guy J, Vaze B. Endobronchial metastasis from renal adenocarcinoma simulating a foreign body. Thorax. 1981;36(3):183–4.
Braman SS, Whitcomb ME. Endobronchial metastasis. Arch Intern Med. 1975;135(4):543–7.
Jariwalla AG, Seaton A, McCormack RJ, Gibbs A, Campbell IA, Davies BH. Intrabronchial metastases from renal carcinoma with recurrent tumour expectoration. Thorax. 1981;36(3):179–82.
Sutton Jr FD, Vestal RE, Creagh CE. Varied presentations of metastatic pulmonary melanoma. Chest. 1974;65(4):415–9.
Zias EA, Owen RP, Borczuk A, Reichel J, Frater RW. An unusual presentation of metastatic colon cancer to the lung. Chest. 1998;113(1):244–6.
Marom EM, Goodman PC, McAdams HP. Focal abnormalities of the trachea and main bronchi. AJR Am J Roentgenol. 2001;176(3):707–11.
Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol. 1988;6(3):527–35.
De Pangher Manzini V, Brollo A, Franceschi S, De Matthaeis M, Talamini R, Bianchi C. Prognostic factors of malignant mesothelioma of the pleura. Cancer. 1993;72(2):410–7.
Fusco V, Ardizzoni A, Merlo F, Cinquegrana A, Faravelli B, De Palma M, et al. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. Anticancer Res. 1993;13(3):683–9.
Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723–31.
Huncharek M, Kelsey K, Mark EJ, Muscat J, Choi N, Carey R, et al. Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. Anticancer Res. 1996;16(3):1265–8.
Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review J Clin Oncol. 1996;14(3):1007–17.
Tammilehto L, Maasilta P, Kostiainen S, Appelqvist P, Holsti LR, Mattson K. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. Respiration. 1992;59(3):129–35.
Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax. 1997;52(6):507–12.
Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 1981;8(3):313–20.
Heller RM, Janower ML, Weber AL. The radiological manifestations of malignant pleural mesothelioma. Am J Roentgenol Radium Ther Nucl Med. 1970;108(1):53–9.
Solomon A. Radiological features of diffuse mesothelioma. Environ Res. 1970;3(4):330–8.
Taylor RA, Johnson LP. Mesothelioma: current perspectives. West J Med. 1981;134(5):379–83.
Wechsler RJ, Rao VM, Steiner RM. The radiology of thoracic malignant mesothelioma. Crit Rev Diagn Imaging. 1984;20(4):283–310.
Steiner RM, Cooper MW, Brodovsky H. Rib destruction: a neglected finding in malignant mesothelioma. Clin Radiol. 1982;33(1):61–5.
Hillerdal G. Pleural plaques and risk for bronchial carcinoma and mesothelioma. A prospective study. Chest. 1994;105(1):144–50.
Miller BH, Rosado-de-Christenson ML, Mason AC, Fleming MV, White CC, Krasna MJ. From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Radiographics. 1996;16(3):613–44.
Benamore RE, O’Doherty MJ, Entwisle JJ. Use of imaging in the management of malignant pleural mesothelioma. Clin Radiol. 2005;60(12):1237–47.
Kawashima A, Libshitz HI. Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR Am J Roentgenol. 1990;155(5):965–9.
Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 1990;154(3):487–92.
Mirvis S, Dutcher JP, Haney PJ, Whitley NO, Aisner J. CT of malignant pleural mesothelioma. AJR Am J Roentgenol. 1983;140(4):665–70.
Ng CS, Munden RF, Libshitz HI. Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases. Clin Radiol. 1999;54(7):415–21.
Rabinowitz JG, Efremidis SC, Cohen B, Dan S, Efremidis A, Chahinian AP, et al. A comparative study of mesothelioma and asbestosis using computed tomography and conventional chest radiography. Radiology. 1982;144(3):453–60.
Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20(20):4199–208.
Patz Jr EF, Shaffer K, Piwnica-Worms DR, Jochelson M, Sarin M, Sugarbaker DJ, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol. 1992;159(5):961–6.
Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172(4):1039–47.
Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114(3):713–22.
Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126(1):11–6.
Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carli MF, Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002;43(9):1144–9.
Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C, et al. Role of 18 F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm. 2004;19(2):149–54.
Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120(1):128–33.
Zubeldia J, Abou-Zied M, Nabi H. 11. Evaluation of Patients with Known Mesothelioma with 18 F-Fluorodeoxyglucose and PET Comparison with Computed Tomography. Clin Positron Imaging. 2000;3(4):165.
Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg. 2005;129(6):1364–70.
Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18 F-FDG PET scans. J Nucl Med. 2007;48(9):1449–58.
Truong MT, Marom EM, Erasmus JJ. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. J Thorac Imaging. 2006;21(2):146–53.
Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 1996;14(1):1–12.
Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005;80(6):1988–92; discussion 92-3.
Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996;111(4):815–25; discussion 25-6.
Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. esection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117(1):54–63. discussion -5.
Schouwink JH, Kool LS, Rutgers EJ, Zoetmulder FA, van Zandwijk N, Vijver MJ, et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg. 2003;75(6):1715–8. discussion 8-9.
Rosado-de-Christenson ML, Abbott GF, McAdams HP, Franks TJ, Galvin JR. From the archives of the AFIP: localized fibrous tumor of the pleura. Radiographics. 2003;23(3):759–83.
Desser TS, Stark P. Pictorial essay: solitary fibrous tumor of the pleura. J Thorac Imaging. 1998;13(1):27–35.
Ferretti GR, Chiles C, Choplin RH, Coulomb M. Localized benign fibrous tumors of the pleura. AJR Am J Roentgenol. 1997;169(3):683–6.
Sandvliet RH, Heysteeg M, Paul MA. A large thoracic mass in a 57-year-old patient. Solitary fibrous tumor of the pleura. Chest. 2000;117(3):897–900.
Dynes MC, White EM, Fry WA, Ghahremani GG. Imaging manifestations of pleural tumors. Radiographics. 1992;12(6):1191–201.
George JC. Benign fibrous mesothelioma of the pleura: MR findings. AJR Am J Roentgenol. 1993;160(1):204–5.
Harris GN, Rozenshtein A, Schiff MJ. Benign fibrous mesothelioma of the pleura: MR imaging findings. AJR Am J Roentgenol. 1995;165(5):1143–4.
Tateishi U, Nishihara H, Morikawa T, Miyasaka K. Solitary fibrous tumor of the pleura: MR appearance and enhancement pattern. J Comput Assist Tomogr. 2002;26(2):174–9.
Tublin ME, Tessler FN, Rifkin MD. US case of the day. Solitary fibrous tumor of the pleura (SFTP). Radiographics. 1998;18(2):523–5.
Usami N, Iwano S, Yokoi K. Solitary fibrous tumor of the pleura: evaluation of the origin with 3D CT angiography. J Thorac Oncol. 2007;2(12):1124–5.
Hara M, Kume M, Oshima H, Shibamoto Y, Iida A, Mori Y, et al. F-18 FDG uptake in a malignant localized fibrous tumor of the pleura. J Thorac Imaging. 2005;20(2):118–9.
Kohler M, Clarenbach CF, Kestenholz P, Kurrer M, Steinert HC, Russi EW, et al. Diagnosis, treatment and long-term outcome of solitary fibrous tumours of the pleura. Eur J Cardiothorac Surg. 2007;32(3):403–8.
Rodriguez-Panadero F, Borderas Naranjo F, Lopez Mejias J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J. 1989;2(4):366–9.
Light RW, Erozan YS, Ball Jr WC. Cells in pleural fluid. Their value in differential diagnosis. Arch Intern Med. 1973;132(6):854–60.
Burgess LJ, Maritz FJ, Taljaard JJ. Comparative analysis of the biochemical parameters used to distinguish between pleural transudates and exudates. Chest. 1995;107(6):1604–9.
Ceyhan BB, Demiralp E, Celikel T. Analysis of pleural effusions using flow cytometry. Respiration. 1996;63(1):17–24.
Metintas M, Ozdemir N, Solak M, Artan S, Ozdemir M, Basaran N, et al. Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions. Respiration. 1994;61(6):330–5.
Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med. 1991;114(4):271–6.
Arenas-Jimenez J, Alonso-Charterina S, Sanchez-Paya J, Fernandez-Latorre F, Gil-Sanchez S, Lloret-Llorens M. Evaluation of CT findings for diagnosis of pleural effusions. Eur Radiol. 2000;10(4):681–90.
Falaschi F, Battolla L, Mascalchi M, Cioni R, Zampa V, Lencioni R, et al. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. AJR Am J Roentgenol. 1996;166(4):963–8.
Shiono T, Yoshikawa K, Takenaka E, Hisamatsu K. MR imaging of pleural and peritoneal effusion. Radiat Med. 1993;11(4):123–6.
Duysinx B, Nguyen D, Louis R, Cataldo D, Belhocine T, Bartsch P, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004;125(2):489–93.
Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122(6):1918–24.
Kramer H, Pieterman RM, Slebos DJ, Timens W, Vaalburg W, Koeter GH, et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med. 2004;45(6):995–8.
Toaff JS, Metser U, Gottfried M, Gur O, Deeb ME, Lievshitz G, et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography. Invest Radiol. 2005;40(4):204–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
de Groot, P.M., Marom, E.M. (2013). Diagnostic Imaging of Lung and Pleural Tumors. In: Diagnostic Pathology of Pleuropulmonary Neoplasia. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0787-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0787-5_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0786-8
Online ISBN: 978-1-4419-0787-5
eBook Packages: MedicineMedicine (R0)